Four days ago, this paper described the expiration of Novo Nordisk's Indian semaglutide patent as a body politics moment — pharma democratization repeating the antiretroviral playbook. The prediction was modest. The reality has been faster, cheaper, and more chaotic than anyone in Copenhagen anticipated.

By Monday morning, at least 42 Indian pharmaceutical companies had launched branded generic versions of semaglutide, the active compound in Ozempic and Wegovy. Yahoo Finance, citing regulatory filings, reported that the number could exceed 50 within the week. [1] Natco Pharma's product, priced at 1,290 rupees per month — approximately $14 — remains the cheapest. But the floor is still falling. Dr. Reddy's, Cipla, Lupin, Sun Pharmaceutical, and Biocon have all entered the market within the four-day window, each undercutting the other by margins measured in single-digit rupees. [2][5]

The speed is not accidental. It is the product of years of preparation. Indian generic manufacturers had been watching the patent clock since 2023, scaling up active pharmaceutical ingredient production, securing regulatory approvals from India's Central Drugs Standard Control Organisation, and lining up distribution networks that span 800,000 pharmacies from Kerala to Kashmir. When the patent expired at midnight on March 20, the supply chain was loaded and waiting. [3]

The Numbers That Matter

India has 77 million people with type-2 diabetes and another 136 million classified as pre-diabetic by the Indian Council of Medical Research. At Novo Nordisk's branded price of approximately $113 per month in India — already a fraction of the American price — semaglutide was accessible to perhaps 3 to 5 percent of the diabetic population. At $14, the economics shift categorically. [2]

Bloomberg's original reporting called this the start of the "generic GLP-1 era." That language understates what is happening. This is not a gradual transition. It is a flood. Jefferies analysts estimate that the Indian semaglutide market could reach $2 billion in annual revenue within 18 months, split among dozens of manufacturers, with average prices continuing to decline as competition intensifies. The active pharmaceutical ingredient itself costs approximately $3 per monthly dose at scale. [2]

The weight-loss dimension, which dominates the American conversation, is secondary in India. Endocrinologists in Delhi, Mumbai, and Chennai are prescribing generic semaglutide primarily for glycemic control. Dr. V. Mohan, chairman of the Madras Diabetes Research Foundation, told the Economic Times that the patent expiry "changes the treatment paradigm for type-2 diabetes in India overnight." Overnight is not a metaphor. His clinic began dispensing generics on March 21. [4]

Novo Nordisk's Counteroffensive

Novo Nordisk has not conceded. The company announced a voluntary price reduction on its branded Ozempic in India to approximately 4,000 rupees per month — roughly $47 — an effort to retain patients who associate the brand with clinical validation. The strategy mirrors the playbook Big Pharma has used in other post-patent markets: compete on trust rather than price, emphasizing the regulatory pedigree of the original versus the generics. [2]

The problem is scale. Novo Nordisk has one manufacturing line in India. The 42 generic manufacturers have hundreds. In the antiretroviral market — the historical parallel this story keeps invoking — branded manufacturers retained less than 10 percent of the Indian market within three years of generic entry. Semaglutide, which requires cold-chain logistics for the injection pen format but is chemically straightforward to produce, may follow a similar trajectory. [3]

Beyond India

China's semaglutide patent expires later in 2026, with at least 15 generic versions already in development. Canada's Patented Medicine Prices Review Board has signaled it will not extend exclusivity. Brazil is expected to approve generics by mid-year. [1]

The United States remains the exception. Novo Nordisk's US patent portfolio — a thicket of formulation, device, and dosing patents — extends some form of protection until 2031 or later. The FDA's approval pathway for peptide generics requires biosimilar-level clinical data. Americans will continue paying $936 per month for what Indians now buy for $14. The ratio is 67 to 1, and widening. [2]

What is happening in India is not a disruption. It is a correction. The question is how long the rest of the world will accept the price it was charged before the correction arrived.

-- PRIYA SHARMA, Delhi